These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28501450)

  • 21. Chronic High-Level Parasitemia in HIV-Infected Individuals With or Without Visceral Leishmaniasis in an Endemic Area in Northwest Ethiopia: Potential Superspreaders?
    van Griensven J; van Henten S; Kibret A; Kassa M; Beyene H; Abdellati S; de Hondt A; Adriaensen W; Vogt F; Pareyn M; Ritmeijer K; Diro E
    Clin Infect Dis; 2024 Jul; 79(1):240-246. PubMed ID: 38193647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
    Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
    Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India.
    Goswami RP; Goswami RP; Basu A; Ray Y; Rahman M; Tripathi SK
    Am J Trop Med Hyg; 2017 Feb; 96(2):285-291. PubMed ID: 27879457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis.
    Bourgeois N; Lachaud L; Reynes J; Rouanet I; Mahamat A; Bastien P
    J Acquir Immune Defic Syndr; 2008 May; 48(1):13-9. PubMed ID: 18300698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Mira JA; Corzo JE; Rivero A; Macias J; De Leon FL; Torre-Cisneros J; Gomez-Mateos J; Jurado R; Pineda JA
    Am J Trop Med Hyg; 2004 Mar; 70(3):298-301. PubMed ID: 15031520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal evaluation of asymptomatic Leishmania infection in HIV-infected individuals in North-West Ethiopia: A pilot study.
    van Griensven J; van Henten S; Mengesha B; Kassa M; Adem E; Endris Seid M; Abdellati S; Asefa W; Simegn T; Debasu D; Bogale T; Gedamu Y; Van Den Bossche D; Adriaensen W; Van der Auwera G; Cnops L; Vogt F; Diro E
    PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007765. PubMed ID: 31593563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Visceral leishmaniasis in patients with HIV infection].
    Ribera E; Cucurull E; Ocaña I; Vallespí T; Gasser I; Juste C
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):73-9. PubMed ID: 7711130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
    Burza S; Mahajan R; Sinha PK; van Griensven J; Pandey K; Lima MA; Sanz MG; Sunyoto T; Kumar S; Mitra G; Kumar R; Verma N; Das P
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3053. PubMed ID: 25101665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of CD4⁺ CTLA-4⁺ Treg cells and CCR5 density in HIV-1-infected patients with visceral leishmaniasis.
    Vallejo A; Abad-Fernández M; Moreno S; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):267-75. PubMed ID: 25142804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visceral Leishmaniasis/HIV co-infection in northeast Brazil: evaluation of outcome.
    Távora LG; Nogueira MB; Gomes ST
    Braz J Infect Dis; 2015; 19(6):651-6. PubMed ID: 26361839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.
    Kubar J; Marty P; Lelièvre A; Quaranta JF; Staccini P; Caroli-Bosc C; Le Fichoux Y
    AIDS; 1998 Nov; 12(16):2147-53. PubMed ID: 9833855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asymptomatic Leishmania infection in HIV-positive outpatients on antiretroviral therapy in Pernambuco, Brazil.
    Guedes DL; Justo AM; Barbosa Júnior WL; Silva EDD; Aquino SR; Lima Junior MSDC; Montarroyos U; Bezerra GSN; Vieira AVB; Pereira VRA; Medeiros ZM
    PLoS Negl Trop Dis; 2021 Jan; 15(1):e0009067. PubMed ID: 33476331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region.
    Pasquau F; Ena J; Sanchez R; Cuadrado JM; Amador C; Flores J; Benito C; Redondo C; Lacruz J; Abril V; Onofre J;
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):411-8. PubMed ID: 15928908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.
    Sinha PK; Bimal S; Singh SK; Pandey K; Gangopadhyay DN; Bhattacharya SK
    Indian J Med Res; 2006 Mar; 123(3):197-202. PubMed ID: 16778304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
    Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
    Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diversity and Within-Host Evolution of Leishmania donovani from Visceral Leishmaniasis Patients with and without HIV Coinfection in Northern Ethiopia.
    Franssen SU; Takele Y; Adem E; Sanders MJ; Müller I; Kropf P; Cotton JA
    mBio; 2021 Jun; 12(3):e0097121. PubMed ID: 34182785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study.
    Costa LDLN; Lima US; Rodrigues V; Lima MIS; Silva LA; Ithamar J; Azevedo CMPS
    BMC Infect Dis; 2023 Mar; 23(1):141. PubMed ID: 36882732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visceral Leishmaniasis in Hospitalized HIV-Infected Patients in Pernambuco, Brazil.
    Guedes DL; Medeiros Z; Dionísio da Silva E; Martins de Vasconcelos AV; Santana da Silva M; Lopes da Silva MA; Ramos de Araújo PS; Miranda-Filho DB
    Am J Trop Med Hyg; 2018 Dec; 99(6):1541-1546. PubMed ID: 30328408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visceral leishmaniasis and HIV coinfection in the Mediterranean region.
    Monge-Maillo B; Norman FF; Cruz I; Alvar J; López-Vélez R
    PLoS Negl Trop Dis; 2014 Aug; 8(8):e3021. PubMed ID: 25144380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.